Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib - 12/08/11
Doi : 10.1016/j.jaad.2006.02.059
Silke C. Hofmann, MD a, Kristin Technau, MD a, Antonia M.S. Müller, MD b, Michael Lübbert, MD, PhD b, Leena Bruckner-Tuderman, MD a, ⁎ 
a From the Departments of Dermatology
b Hematology and Oncology, University of Freiburg
Reprint requests: Leena Bruckner-Tuderman, MD, Professor and Chair, Department of Dermatology, University of Freiburg, Hauptstrasse 7, D-79104 Freiburg, Germany.Freiburg, Germany
Abstract |
Hypereosinophilic syndrome is a myeloproliferative disorder defined by unexplained, persistent hypereosinophilia with cutaneous or systemic involvement. We describe a patient with coexistence of hypereosinophilic syndrome and bullous pemphigoid. Treatment with the novel tyrosine kinase inhibitor imatinib mesylate resulted in durable remission of hypereosinophilia and skin lesions.
Le texte complet de cet article est disponible en PDF.Abbreviations used : BP, DIF, HES
Plan
| Funding sources: Supported in part by grants Br1475/6-3 from the German Research Council, DFG (to L. B-T.) and from the German Dermatological Society, DDG (research fellowship to S. H.). Conflicts of interest: None declared. |
© 2007
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 56 - N° 5S
P. S68-S72 - mai 2007 Retour au numéro
Article précédent
- Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies
- Gregory J. Fulchiero, Heather Salvaggio, Joseph J. Drabick, Kevin Staveley-O’Carroll, Elizabeth M. Billingsley, James G. Marks, Klaus F. Helm
- A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia
- Adam R. Taintor, Kristin M. Leiferman, Takashi Hashimoto, Norito Ishii, John J. Zone, Christopher M. Hull
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?